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-Aminobutyric acid typeA (GABAA) receptors aremembers
of the Cys-loop superfamily of ligand-gated ion channels. Upon
agonist binding, the receptor undergoes a structural transition
from the closed to the open state, but themechanismof gating is
not well understood. Here we utilized a combination of conven-
tional mutagenesis and the high precision methodology of
unnatural amino acid incorporation to study the gating inter-
face of the human homopentameric 1 GABAA receptor. We
have identified an ion pair interaction between two conserved
charged residues, Glu92 in loop 2 of the extracellular domain
and Arg258 in the pre-M1 region.We hypothesize that the salt
bridge exists in the closed state by kinetic measurements and
free energy analysis. Several other charged residues at the
gating interface are not critical to receptor function, support-
ing previous conclusions that it is the global charge pattern of
the gating interface that controls receptor function in the
Cys-loop superfamily.
Fast inhibitory neurotransmission in the adult mammalian
central nervous system is primarily mediated by the amino acid
-aminobutyric acid (GABA).2 So far, three types of GABA
receptors have been identified, termed GABAA, GABAB, and
the homopentameric 1 GABAA receptor, also known as
GABAC (1, 2). Although GABAB is a G protein-coupled recep-
tor, GABAA andGABAC receptors are homologous but distinct
members of the Cys-loop superfamily of ligand-gated ion chan-
nels, which also includes the nicotinic acetylcholine (nAChR),
serotonin, and glycine receptors. Members of this superfamily
are composed of five subunits arranged around a central ion-
conducting pore, with each subunit consisting of a large extra-
cellular domain, four transmembrane helices (M1–M4), and a
large intracellular loop. The newest member of this family, the
GABAC receptor (3), is expressed predominantly on retinal
neurons, although recent studies indicate a wide distribution
throughout the central nervous system (4–6).
The binding of agonist to a Cys-loop receptor triggers a com-
plex structural transition that results in the opening of a “gate,”
allowing ions to flow through the channel (7). Identifying the
linkage pathway has been limited by the lack of a complete
atomic-resolution structure of any fast synaptic receptor. How-
ever, two breakthroughs have propelled the field into the struc-
tural age. The first is determination of the crystal structure of
acetylcholine-binding protein (8), which is homologous to the
extracellular domain of the nAChR and, by extension, all Cys-
loop receptors. This structural template provides critical
insights into the nature of the binding site, but, of course, the
ion channel and its gate are missing from such structures. Sec-
ond, a refined electron microscopy structure of the Torpedo
acetylcholine receptor by Unwin and co-workers (Protein Data
Bank code 2BG9) has shed light onto the global structure and
has suggested molecular determinants of functional mecha-
nisms in Cys-loop receptors (9–11).
The available structural information reinforced previous
conclusions on the modular nature of Cys-loop receptors, with
the extracellular domain being well defined and primarily com-
posed of sheets and the transmembrane domain exclusively
helical. A large number of ionic residues are found where these
two domains meet, and many studies have suggested that spe-
cific ion pair interactions make important contributions to the
gating mechanism (12–16). We have described this region as
the “gating interface,” and both experiments and analyses
across theCys-loop superfamily showed that, whereas the over-
all charging pattern of the gating interface is conserved, specific
ion pair interactions are not (16, 17). As such, it is risky to
conclude that a particular ion pair interaction that may be
important in one Cys-loop receptor will be important through-
out the superfamily.
An especially prominent ion pair interaction at the gating
interface of the Torpedo nAChR structure is shown in Fig. 1.
The side chains of subunit residuesGlu45 in loop 2 andArg209
in the pre-M1 segment are in close proximity, and recent stud-
ies by Lee et al. (15) establish that they form a salt bridge in
muscle-type nAChR. These residues align with Glu92 and
Arg258 in the GABAC 1 subunit (Fig. 1). The GABAC receptor
is distinct in several ways from the muscle-type nAChR. The
GABAC receptor is homopentameric, inhibitory (anion con-
ducting), and displays kinetics on the seconds time scale. The
muscle-type nAChR is heteromeric ((1)21), excitatory
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(cation conducting), and displays kinetics on the milliseconds
time scale. Thus we were interested in whether the ion pair
interaction seen in the nAChR is also important in the GABAC
receptor. Here we describe studies of this and other potential
interactions in the gating interface of the GABAC receptor
using both conventional and unnatural amino acid mutagene-
sis. We find that GABAC receptor 1 subunits form the same
ion pair interaction as previously identified in the nAChR (15).
Based on kinetic data, we propose that the salt bridge stabilizes
the receptor in the resting state and that agonist binding to the
receptor leads to the breaking of the salt bridge, triggering the
opening of the ion channel.
MATERIALS ANDMETHODS
Cloning, Mutagenesis, and mRNA Synthesis—GABAC recep-
tor subunits were derived from pcDNA3.1 (Invitrogen) con-
taining the complete coding sequence for the human 1 recep-
tor subunit, kindly provided by Dr. Sarah C. R. Lummis
(University of Cambridge, UK). Wild-type receptor coding
sequences were then subcloned into the oocyte expression vec-
tor plasmid pGEMHE. The 3- and 5-untranslated regions
from a Xenopus -globin gene in the vector led to an enhance-
ment of expression by several hundred-fold (18). Mutations in
the cDNA were made using the QuikChange mutagenesis kit
(Stratagene). Plasmidswere linearizedwithNheI (NewEngland
Biolabs, Ipswich,MA) and used as template to producemRNAs
using the T7 mMESSAGE mMACHINE kit from Ambion
(Austin, TX). The resulting mRNA is stored at80 °C.
Electrophysiology and Data Analysis—Stage VI oocytes of
Xenopus laevis were employed. Electrophysiology recordings
were performed 48–72 h after injection in two-electrode volt-
age clamp mode using the OpusXpress 6000A (Molecular
Devices, Axon Instruments, Union City, CA). Holding poten-
tials were 60 mV. Drug applications were 40–130 s in dura-
tion. Data were sampled at 125 Hz and filtered at 50 Hz. All
drugs were diluted to the desired concentration with ND96
buffer. EC50, IC50, and Hill coefficients were calculated by fit-
ting the does-response relation to the Hill equation (19). All
data are reported as mean  S.E. Maximal currents elicited
by GABA, Imax(GABA), and by muscimol, Imax(muscimol), were
measured at saturating concentrations on the same oocytes.
The relative efficacy (), defined as the ratio of Imax(muscimol)/
Imax(GABA), was calculated for each cell then averaged, and is
reported as mean  S.E. All chemicals were purchased from
Sigma.
For kinetic measurements, drug applications began at a rate
of 0.023 ml/s for 28 s and then decreased to 0.0033 ml/s for
102 s. Measurements of on-kinetics, especially at the higher
GABA concentrations, are limited by two factors. The most
rapid kinetics was limited by the speed of the drug delivery
system. Chamber volume was 100 l, so that solution
exchange in the entire chamber occurred with a time constant
of4 s. However, the drug pipette was situated just a few mil-
limeters from the oocyte, so that solution changes were faster
near the oocyte; we estimate that the fastest time constant for
solution change near the oocyte was 0.5 s. Additional experi-
ments, conducted at exchange rates up to 0.067 ml/s, estab-
lished that the derived kinetic parameters are not detectably
dependent on the rate of drug application. The slowest on-ki-
netics was limited by the longest drug application time, 130 s
(limited by the 1-ml drug reservoir), which allowed for time
constants as long as44 s. Activation rate constants (k 1/)
of 0.023–2 s1 are therefore in the measurable range. The
rate constants k of the individual activation traces were calcu-
lated by fitting the activation phase to a first-order exponential
function with a sloping baseline (pCLAMP software, Axon
Instruments). Values of k were then averaged and plotted
against [GABA]; this plot was fitted as a straight line (Fig. 3,
B–E). The apparent bimolecular binding rate constant kact
equals the slope of this plot.
For the deactivation phase, chambers were perfused at 0.05
ml/s until the current returned to the baseline. The rate con-
stants of the individual deactivation traces were calculated by
fitting the deactivation phase to a first-order exponential func-
tion. The deactivation rate constant was averaged across all
GABA concentrations. In general, it was possible to measure
kinetics at GABA concentrations in the range of EC50 to 10
times EC50 (5 times EC50 for wild-type receptor). Kinetic
parameters are difficult to obtain for lower GABA concentra-
tions because of the small current size.
Unnatural Amino Acid Suppression—Unnatural amino acid,
nitrohomoalanine (Nha), was synthesized, conjugated to the
dinucleotide deoxycytosine adenosine (dCA), and ligated to
truncated 74-nucleotide tRNA as previously described (20).
Briefly, the aminoacyl-tRNA was deprotected by photolysis
immediately prior to co-injection with mRNA containing an
amber (TAG) stop codon at position 92. Negative and positive
controls were performed as previously reported (21).
Western Blotting—To detect surface expression for several
mutants, a hemagglutinin epitope tag was incorporated at the
N-terminal in the 1 subunit (between positions 2 and 3). Con-
trol experiments show a negligible effect of this epitope on
EC50. 48–72 h after injection, 12 oocytes were incubated in
hypotonic solution (5 mM HEPES, 5 mM NaCl) for 10 min, and
then the vitelline/plasma membranes were isolated by physical
dissection. The pellet and supernatant were mixed with 5 l of
2 SDS loading buffer, and SDS-PAGE was performed in 15%
Tris-Cl ReadyGels (Bio-Rad Laboratories). The samples were
FIGURE 1. A, image showing the proximity of Glu45 and Arg209 (space-filling
models) in the nAChR. Numbers in parentheses show the corresponding resi-
dues in the GABAC 1 subunit. The structure is the full model of an  subunit
of the Torpedo nAChR developed by Unwin (9) (PDB code 2BG9). B, sequence
alignment for loop 2 andpre-M1 (16). All subunits are fromhuman except Tor
 (Torpedo californica) and nACh 1, 1, , and , which are mouse muscle.
Residues corresponding to Glu92 and Arg258 studied here are bold.
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subjected to Western blot analysis using the anti-hemaggluti-
nin antibody and visualized using an ECL detection kit (Amer-
sham Biosciences).
RESULTS
Studies of the Human GABAC Receptor 1 Subunit—As in
other members of the Cys-loop superfamily, the gating inter-
face of theGABAC receptor is rich in charged residues.Wehave
studied three positions in loop 2, which frequently has a larger
number of charged residues, both by conventional mutagenesis
and unnatural amino acidmutagenesis. The results are given in
Table 1. In loop 2, Glu92 is conserved as negatively charged
across the entire Cys-loop family, and it aligns with the previ-
ously mentioned Glu45 of the muscle-type nAChR. Its impor-
tant role in receptor function is confirmed in the GABAC 1
subunit, because the charge reversal mutation E92R gave non-
functional receptors.Western blot analysis confirms that prop-
erly assembled receptors reached the cell surface (supplemental
Fig. S1), establishing that the E92R mutation affected receptor
function rather than folding, assembly, or trafficking. Previous
studies show that introducing a positive charge at this position
either lowers the EC50 significantly in nAChR and glycine
receptor 1 or raises the EC50 modestly in GABAA 1 subunit,
demonstrating an important role in gating for this charged res-
idue (12, 14, 16). Two other anionic residues in loop 2 were also
probed. Asp-94 is conserved as negatively charged in GABAA 
subunits and nAChR , , and  subunits, but not throughout
the Cys-loop family; Asp-96 is conserved as negatively charged
in all inhibitory Cys-loop receptors. In contrast to E92R, both
D94R and D96R areminimally perturbing, consistent with pre-
vious observations on the remarkable tolerance in general of
the gating interface to such charge reversal mutations (16, 17).
A classic test for a specific ion pair interaction is the charge-
swapping experiment; i.e. if Glu92 experiences an electrostatic
interaction with a specific cationic residue, then the nonfunc-
tional E92R mutant often can be “rescued” by converting the
cationic partner to an anion. Based on the 2BG9 structure, four
positively charged residues could be fairly close toGlu92: Arg257
and Arg258 in pre-M1 and Arg316 and Lys321 in the M2–M3
linker. Only Arg258 is universally conserved as a positively
charged group. The nonfunctional E92Rmutant is fully rescued
by combination with R258E in pre-M1 but not by R257D,
R316D, or K321E. The double mutant E92R/R258E shows a
modest 4-fold decrease in EC50 (Table 1 and Fig. 2). The single
charge reversal mutation R258E produced receptors that can-
not traffic to the cell surface, indicating the positive charge is
involved in receptor expression, folding, and/or assembly (sup-
plemental Fig. S1). Previous work on the corresponding residue
in glycine receptor1 and nAChR7 receptors show contribu-
tions to agonist potency and efficacy (22, 23). The other three
positive sites we studied, Arg257, Arg316, and Lys321, are not
critical, because single charge reversal mutations all produced
functional receptors with modest shifts in EC50. Therefore,
Glu92 and Arg258 satisfy several criteria expected of residues
that lie on the “principal pathway” coupling agonist binding to
receptor gating: they are located in close proximity to each
other at the gating interface, receptor function can be rescued
by charge swapping, and they are conserved in all members of
the Cys-loop receptors.
Unnatural Mutant, E92Nha—To explore more fully the role
of Glu92 in gating, we incorporated an unnatural amino acid
that is isosteric and isoelectronic to Glu but does not contain a
negative charge. The residue is Nha, the nitro analog of Glu
(Fig. 2C). Charge neutralization atGlu92would destroy any ion-
pairing interaction with Arg258. As shown in Table 1 and Fig.
2B, incorporation of Nha at position 92, E92Nha, resulted in an
11-folddecrease in EC50 forGABA.TheE92Nhamutant behav-
ior suggests that charge neutralization greatly affects the salt
bridge interaction, producing a gain-of-function channel.
Conventional Mutant, E92D—Because the side-chain length
of Asp is one carbon group shorter than that of Glu (Fig. 2C),
one expects this mutation to weaken the electrostatic interac-
tion with Arg258 by moving the two charged groups further
apart. Glu92 can be replaced by the Asp residue, producing
functional receptors with a 40-fold decrease in EC50 compared
with the wild-type receptors. This apparent gain-of-function
mutation also has important mechanistic consequences, as dis-
cussed below.
Kinetics of GABA Responses—Fig. 3A superimposes normal-
ized waveforms of responses to GABA pulses for wild-type,
E92R/R258E, E92Nha, and E92D receptors. Kinetic analysis is
simplified by the fact that GABAC receptors display little mac-
roscopic desensitization. The very differentwaveforms indicate
interesting variations. To evaluate the kinetic properties of the
wild-type and mutant receptors, response waveforms were
recorded at various GABA concentrations. Kinetic analysis of
the wild-type receptor revealed a GABA concentration-
dependent activation rate, with an apparent bimolecular rate
constant (kact) of 0.156 M1 s1 (Fig. 3B and Table 2). We
consider that this parameter is reliable to  15%. As expected
from most models, the deactivation phase for the GABAC
receptor was well fitted by a single exponential and showed
little or no concentration dependence (24, 25). This decay had a
rate constant kdeact of 0.038 s1.
The single mutants E92Nha and E92D both show increased
values for kact and decreased values for kdeact (Fig. 3 (C and D)
and Table 2). Both effects are larger for the more disruptive
E92D mutant. The double mutant E92R/R258E has distinct
TABLE 1
Mutations at the gating interface in GABAC 1 subunits
Mutants EC50 for GABA nH
M
Wild type 1.34 0.04 2.2 0.1
E92R N.F.a
E92D 0.03 0.002 1.4 0.1
E92Nha 0.12 0.004 1.6 0.1
D94R 0.3 0.02 2.2 0.2
D96R 5.7 0.5 2.2 0.4
R257D 0.37 0.003 3.5 0.1
R258E N.E.b
R316D 8.4 0.2 1.6 0.1
K321E 3.3 0.2 2.2 0.2
E92R/R257D N.S.c
E92R/R258E 0.35 0.004 3.1 0.1
E92R/R316D N.S.
E92R/K321E N.S.
aN.F., nonfunctional; no response to applied GABA, but surface expression of
receptor confirmed by Western blot.
bN.E., no expression, as confirmed by Western blot.
cN.S., no signal; no response to applied GABA, surface expression not independ-
ently verified.
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kinetic properties (Fig. 3E and Table 2). The activation rate is
roughly half that of wild type, and the deactivation rate is sig-
nificantly decreased to one-fourth of the value for wild-type
receptors.
The 1GABAC receptor used in this study has a single-chan-
nel conductance of2 pS (26, 27). The resulting small currents
vitiate systematic kinetic studies using single-channel analysis.
Functional Properties of E92R/R258E and Wild-type Recep-
tors—Because the E92R/R258E mutations we are evaluating
occur at the gating interface and are quite remote from the
agonist binding site (28), we expect changes in EC50 to reflect
alteration of gating more than binding. To verify this, we com-
pared several functional characteristics of the two receptors;
the results are summarized in Table 3. The reversal potential of
GABA currents mediated by the E92R/R258E mutant receptor
was the same as for the wild-type receptor; both were close to
26mV, indicating the currents aremainly carried by chloride,
as expected. The GABAC-competitive antagonist, TPMPA
((1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid), re-
duced the GABA current with an IC50 of 1.7 M for E92R/
R258E, roughly 3-fold different from thewild-type receptor (5.5
M). To examine the affinity of TPMPA for both receptors,
Schild plots were generated (supplemental Fig. S2). Kd values
obtained were 2.41 M and 0.90 M, for wild-type and mutant
receptors, respectively, again a roughly 3-fold shift.
Zinc ion acts as an allostericmodulator of the GABAC recep-
tor. Previous work has identified His-157 in the extracellular
domain to be involved in Zn2 block (29). Zinc ions blocked the
E92R/R258E mutant receptor with an IC50 of 46 M, whereas
the IC50 for wild type was 52 M, indicating that the mutant
receptor does not disrupt down-modulation by zinc.
The behavior of the open channel blocker, picrotoxin, was
also examined. Picrotoxin is considered to bind in the pore
region of the receptor (30, 31). The E92R/R258E mutant chan-
nel is relatively insensitive to picrotoxin, with an 8-fold increase
in IC50.
Finally, we measured the relative efficacy () of muscimol, a
GABAC partial agonist, for wild-type receptors as well as the
double mutant receptors (Table 3). The  for the E92R/R258E
receptor is substantially increased over that of the wild-type,
from0.61 to 1.09, convertingmuscimol fromapartial agonist to
a full agonist. In summary, for the E92R/R258E channel, the
current is inhibited by TPMPA, down-modulated by Zn2,
blocked by picrotoxin, and gated by muscimol, confirming the
double mutant channel has the general pharmacological prop-
erties of the 1 receptors.
DISCUSSION
The present work reveals a significant ion pair interaction at
the gating interface of the GABAC receptor. Although the sin-
FIGURE 2. A, representative voltage-clamp current traces from oocytes expressing E92R/R258E (left), E92Nha (nitrohomoalanine, middle), and E92D (right).
Horizontal bars represent application of GABA (micromolar). B, dose-response relations of GABA-mediated responses from oocytes expressing wild-type,
E92R/R258E, E92Nha, and E92D receptors. EC50 and nH values are given in Table 1. C, structures of Glu, Asp, and unnatural amino acid Nha.
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glemutant E92R is nonfunctional, and the singlemutant R258E
does not express on the cell surface, the double mutant E92R/
R258E is fully functional, with an EC50 4-fold less than wild
type. In addition, the double mutant displays global functional
and pharmacological characteristics that are typical for a
GABAC 1 receptor. As noted earlier, the comparable pair,
Glu45–Arg209, has been shown to
interact in the muscle-type nAChR
(15). Thus, unlike several other ion
pairs of the gating interface that
have been ascribed important roles
in receptor function (12–14, 16), the
pair considered here may well be
important throughout the Cys-loop
superfamily.
That the Glu92–Arg258 interac-
tion really is an ion pair is supported
by several observations. Note that
the typical tool for establishing a
pairwise interaction, a mutant cycle
analysis (32), is not applicable here
because the key single mutants do
not produce functional receptors.
Perhaps the most telling evidence
for ion pairing results from the
unnatural amino acid Nha. The side
chain of Nha is isosteric and isoelec-
tronic to that of glutamate; the only
substantive difference is the lack of a
negative charge. The Nha mutant
shows an 11-fold decrease in EC50,
suggesting charge plays an impor-
tant role.Note that, althoughunable
to form an ion pair, the nitro group
of Nha can hydrogen bond to the
side chain of Arg258. Although the
hydrogen bond is expected to be 10-
to 20-fold weaker than the analo-
gous interaction with a carboxylate
(20), this could account for the fact
that the Nha receptor is still func-
tional. Apparently, not only is the
Glu92–Arg258 interaction impor-
tant, but it is also significantly geo-
metrically constrained. The char-
ge-conserving E92D mutation
produces a larger EC50 shift than
the charge-neutralizing Nha mu-
tation. Apparently, the shorter
Asp side chain versus Glu signifi-
cantly compromises the Glu92–
Arg258 interaction. Because ion
pairs are not usually considered to
FIGURE 3. A, normalized current responses to 1 M GABA from the oocyte expressing E92Nha (green), E92D
(red), andE92R/R258E (pink), respectively, comparedwithwild-type receptor (black).Bars represent application
of GABA. The traces show clearly themore rapid activation and slowly deactivation for both E92Nha and E92D
receptors. The traces show the more slowly activation and deactivation for E92R/R258E receptors. B, kinetics
properties of wild-type receptor. C, kinetics properties of E92Nha receptor. D, kinetics properties of E92D
receptor. E, kinetics properties of E92R/R258E receptor.
TABLE 2
A comparison of kinetic parameters for the wild type, E92Nha, E92D, and E92R/R258E receptors
kact RT ln(kact,WT/kact,mut) kdeact RT ln(kdeact,WT/kdeact,mut)
mM1 s1 kcal mol1 s1 kcal mol1
wild type 0.156 0.006 0.038 0.001
E92Nha 0.28 0.014 0.35 0.017 0.001 0.48
E92D 0.37 0.024 0.52 0.0057 0.0001 1.12
E92R/R258E 0.079 0.004 0.40 0.010 0.001 0.79
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be especially sensitive to distance, this significant effect sug-
gests a substantial geometric constraint.
Several lines of evidence suggest that theGlu92–Arg258 inter-
action plays a significant role in receptor gating. The double
mutant E92R/R258E is functional, and it converts the partial
agonist muscimol to a full agonist. Such observations are typi-
cally interpreted to mean that the mutation has affected the
open probability of the receptor, such that a drug that cannot
produce a large Popen for the wild-type receptor, a partial ago-
nist, can do so for the doublemutant. The 5-fold drop in EC50 of
muscimol seenwith the doublemutant is completely consistent
with this analysis. If we assume that binding of two ligands is
required to efficiently gate the channel, the 60% efficacy of
muscimol for the wild type indicates that the ratio of opening
to closing rates, /	, for the doubly liganded receptor is
1.5. Increasing this ratio to a value of 30, giving an efficacy of
97%, would account for the 5-fold drop in EC50, because
this parameter varies as roughly the square root of 	. We
interpret the 4-fold drop in EC50 for GABA activation to
reflect a similar increase in 	 for the E92R/R258E mutant.
Similar conclusions are reached if we assume binding of
three ligands (see below).
The double mutant also affects the open channel blocker
picrotoxin, raising IC50 by 8-fold. The picrotoxin binding site is
in the channel region, far removed from the agonist binding
site. In our interpretation of this finding, the doublemutant has
altered the structure in the gating region, not the agonist bind-
ing site. It is true that certain types of open-channel blockers are
expected to show varying potency as	 varies, even if themuta-
tion changes the binding site; however, the most straightfor-
ward models predict that IC50 for a channel blocker would
decrease as 	 increases (33). We believe that the lowered
potency for picrotoxin does indicate that the Glu92–Arg258 pair
directly influences the binding of picrotoxin at a site within the
channel region (30, 31).
Not surprisingly, modulation of the channel by Zn2 is not
affected by the E92R/R258E mutation, because the Zn2 bind-
ing site is remote from both the agonist binding site and the
channel gate. The competitive antagonist TPMPA does show
an 3-fold enhancement of binding in the double mutant.
TPMPA is a larger molecule than GABA, and it may be that,
while blocking the binding site, TPMPA can be closer to the
Glu92–Arg258 pair, such that it responds to mutations there
either directly or through an allosteric effect.
As with other structural insights into receptors and receptor
models, the image of the nAChR shown in Fig. 1 begs the ques-
tion as to which state of the receptor we are viewing. Several
lines of evidence suggest that, at least for the GABAC receptor,
the ion pair probed here is present in the closed state and is
broken on going to the open state. We assume the ion pair
stabilizes the state in which it is present. Weakening the ion
pair, either by charge neutralization (E92Nha) or by disrupting
the geometry (E92D) destabilizes that state and lowers EC50.
The simplest way to interpret this is that weakening the Glu92–
Arg258 interaction destabilizes the closed state, which would
thereby lower the barrier to the open state.
The homomeric 1 receptor displays activation and inactiva-
tion kinetics that are anomalously slow among Cys-loop recep-
tor family members, although the actual kinetics appear to vary
by up to 3-fold between oocyte andmammalian cell expression
systems (34, 35). The previously available data do, however,
agree in suggesting that the open state of the channel is much
more likely to be associated with the presence of three or more
bound GABA molecules than with fewer bound agonist mole-
cules. Our interpretation that the highly sensitive E92D and
E92Nha mutants have destabilized close states then suggests
that the open state of the channel might require fewer bound
agonistmolecules. This hypothesis is consistentwith our obser-
vation that the Hill coefficients of the dose-response relations
decrease from the wild-type value of 2.2 to 1.4 and 1.6 for the
highly sensitive mutants. Other explanations are possible, and
we recognize that another mutant, R316D, is less sensitive than
wild-type but it too has a lower Hill coefficient.
The macroscopic rate constants of Table 2 support this
view of a destabilized closed state. These numbers are nec-
essarily complex, with kact reflecting a composite of binding
and unbinding processes and channel opening (the latter is
generally described by the rate constant ). That binding is
involved is established by the increase in kact with [GABA].
The requirement for multiple bound agonist molecules leads
one to predict that kact should increase more than linearly
with [GABA] (33). However, this effect is expected to be
most pronounced for [GABA]  EC50, and for the usual
reasons, our measurements are most precise at larger
[GABA]. If we assume that mutations at Glu92/Arg258 influ-
ence gating more than binding, as argued above, then differ-
ences in kact can be ascribed to differences in .
In contrast, kdeact is independent of [GABA]; so we associate
this unimolecular rate constant with the rate constant for chan-
nel closing, . With these assumptions about kinetics, the free
energy diagrams of Fig. 4 can be constructed.
We assume that the ion pair is completely absent in the open
state, and so the open state energy is unaffected by the muta-
tions studied here. Then, the differences in kdeact set the relative
positions of the transition states that separate open and closed
states. The mutations destabilize the closed state. This destabi-
lization must be more than the destabilization of the transition
state by an amount that corresponds to the acceleration of the
opening rate. That is, for E92Nha and E92D, the closed state
must be destabilized by 0.48 0.35 0.83 kcal/mol and 1.12
0.52 1.64 kcal/mol, respectively. This simple model rational-
TABLE 3
Functional comparison of wild-type and E92R/R258E receptors
GABA concentration for IC50 for wild-type and E92R/R258E is 4 M and 1 M
(EC95), respectively. Schild plots are shown in supplemental Fig. S2.
Wild type E92R/R258E
Reversal potential (mV) 27.1 0.8 25.9 0.7
IC50 for TPMPA (M) 5.5 0.3 1.7 0.1
nH 1.8 0.1 1.6 0.1
Kd (M) 2.41 0.90
IC50 for zinc (M) 52 2 46 5
nH 1.9 0.1 1.5 0.2
IC50 for picrotoxin (M) 4.5 0.2 37 5
nH 0.9 0.03 0.7 0.04
EC50 for muscimol (M) 3.0 0.1 0.56 0.02
nH 1.6 0.1 2.5 0.2
 0.61 0.02 1.09 0.03
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izes the acceleration of kact and the deceleration of kdeact caused
by mutations at Glu92.
We can also estimate the extent to which the Glu92–Arg258
interaction is present in the transition state for channel open-
ing. For the E92Nha mutant, the value is 0.48/0.83  58%; for
E92D it is 1.12/1.64  68%. The more severe E92D mutation
produces an earlier transition state, as would be expected based
on the greater destabilization of the starting (closed) state. Pre-
sumably, the wild-type receptor would have a later transition
state than either mutant, perhaps with 50% of the ion pair
interaction present. This value is consistent with Auerbach’s
free energy analyses of residues in this region, which establish

values that are intermediate between those of the agonist bind-
ing site region and those of the transmembrane region (36, 37).
In summary, we have established an important ion pair inter-
action between Glu92 and Arg258 in the gating interface of the
GABAC receptor, the second example of this interaction being
important in aCys-loop receptor. Several lines of reasoning and
earlier work suggest that the ion pair probed here plays an
important role in channel gating. We propose that the Glu92–
Arg258 ion pair stabilizes the closed state of the receptor and is
completely broken upon going to the open state. Free energy
analysis suggests the ion pair is50% broken at the gating tran-
sition state, consistentwith othermodels of receptor activation.
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FIGURE 4. Schematic energy diagram of the transition from the agonist
bound closed state to open state of wild-type (solid line), E92Nha
(dashed line, left), and E92D (dashed line, right). Numbers are the free
energy differences (kcal mol1) between wild-type and mutant receptor.
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